Fiji’s HIV epidemic has intensified sharply and a mobile outreach service is now drawing a clearer picture of where the virus is concentrated. New national diagnoses jumped 281 percent between 2023 and 2024 to 1,583 cases, with young people and indigenous Fijians bearing the heaviest burden — 60 percent of new infections are among 15 to 29-year‑olds, and 93 percent of those diagnosed in the first half of 2025 were iTaukei Fijians. At the same time, Medical Services Pacific’s Moonlight Program has reported a high yield from targeted, after‑hours testing that health officials say exposes gaps in conventional services.
Between December 2025 and March 2026 the Moonlight Program conducted 1,464 HIV and STI tests across Fiji’s three divisions, operating in informal settlements, nightlife precincts and other locations many people find unsafe attending during daytime hours. The outreach is delivered from a van that parks after midnight and by teams that include peer educators connected to SAN Fiji and Rainbow Pride Foundation Fiji — organisations trusted by sex workers and LGBTQI+ communities.
The program’s reactive case rate was 8.9 percent — nearly one in ten people tested returned a reactive result — and MSP reports that for a majority of these clients it was their first HIV test. That high reactive rate is presented by MSP as evidence of precise targeting rather than program failure: the Moonlight teams deliberately seek populations and locations where HIV transmission is concentrated and where people have previously been excluded or deterred from facility‑based services.
Demographics from the quarter reinforce that targeting. Forty‑one percent of those tested were under 25 years old, aligning with national data showing the epidemic skewed to younger people. The service reached a balanced gender mix — 48 percent male, 47 percent female and 5 percent other gender identities — indicating the outreach is engaging diverse key populations rather than a single demographic group.
Crucially, the Moonlight teams emphasise linkage to care. MSP recorded 44 clients referred to the Ministry of Health for HIV management and initiation of antiretroviral therapy during the quarter, and they report that referrals often included accompaniment through the pathway to treatment. Closing the interval between a reactive test and treatment start is a recognised bottleneck in harm‑reduction work; MSP says its model is designed explicitly to reduce that loss to follow‑up.
The Moonlight work is funded through a Fiji sub‑grant of US$125,000 under the International Planned Parenthood Federation’s Voices of Resilience program, financed by the Australian Government (DFAT) and the New Zealand Government (MFAT). MSP is an implementing partner in the IPPF initiative, which aims to provide mobile, targeted outreach to key populations that conventional health systems struggle to reach.
This latest tranche of data matters because it offers recent, concrete evidence that targeted, community‑led outreach can both identify previously undiagnosed infections and link people into treatment — a necessary step if Fiji is to counter the rapid rise in diagnoses recorded in 2024 and the disproportionate impact on young and iTaukei communities. The results also underline calls from community groups and some health advocates for expanded, culturally safe testing and care models that operate beyond standard clinic hours and settings.
Leave a comment